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219 A review of hospital and hospital in the home (HiTH) services at
a paediatric cystic ﬁbrosis (CF) centre
F.C. Moran1, C. Barr1, M. Kerr1, E. Tannenbaum1. 1The Royal Children’s
Hospital, Physiotherapy Department, Victoria, Australia
Objectives: The Royal Children’s Hospital in Melbourne cares for approximately
250 patients with CF. Patients admitted to hospital may spend some of the admission
in HiTH whilst others remain in hospital. Routine physiotherapy service in hospital
includes twice daily supervised sessions on weekdays, and once daily on weekends.
HiTH physiotherapy service includes once daily supervised session on weekdays
only. This review aimed to examine HiTH utilisation and compare HiTH outcomes
to hospitalisation in CF.
Methods: A retrospective audit of patient records was performed covering a 24
month period.
Results: 246 patient records were reviewed. 338 admissions occurred for 117
patients. 13 admissions involved inter-hospital transfer and were not included further
leaving 375 admissions. 221 (59%) admissions were conducted solely in hospital
and 154 (41%) included some period of HiTH (mean 9.9 days, range 3–174). When
16 admissions of excessive length (>20 days) were excluded, average length of stay
was 12.6 days for hospital-only admissions, and 14.4 days for those including HiTH
(p = 0.00). Hospital-only admissions had signiﬁcantly lower FEV1 (% predicted) at
admission (60.6% vs 70.7%, p = 0.00) but resulted in a greater absolute percentage
increase in FEV1 from admission to discharge (15.7% vs 8.7%, p = 0.02).
Conclusion: This review shows that CF admissions when they involved were longer
and resulted in a smaller increase in FEV1. However, these patients had higher FEV1
at admission. With increasing reliance on home-based provision of hospital services
it is important to ensure that these services are similarly effective, and beneﬁcial
in the short and long-term for patients.
220 Safety, tolerability and patient preference of intravenous
colistimethate sodium delivered by bolus compared to infusion
in adults with cystic ﬁbrosis
C. Evans1, N. Gilday1, R. Davies1, B. Ahitan1, R. Rashid1, J.L. Whitehouse1,
E.F. Nash1. 1West Midlands Adult Cystic Fibrosis Centre, Heart of England NHS
Foundation Trust, Birmingham, United Kingdom
Background: Intravenous (IV) colistimethate sodium (CS) is used to treat pul-
monary exacerbations in CF patients and is usually delivered by infusion over
approximately 30 minutes. CS can also be delivered by bolus injection via Totally
Implantable Venous Access Devices (TIVADs), but there is currently little evidence
to support the safety, tolerability and patient preference.
Methods: We identiﬁed patients that had received CS by both infusion and bolus
in our large regional adult CF centre from 2012–2013. We recorded baseline
clinical parameters (at the time of switching to bolus injection) as well as the ease,
convenience, time, side effects and patient preference in drawing up and delivering
bolus CS.
Results: 26 subjects (14 male) (median (IQR) age 29 (25−35) yrs, FEV1 53
(39−68)% predicted) were recruited. These 26 subjects had received 84 courses
of either bolus or infusion CS. Bolus was reported to be easier to reconstitute and
administer (18 (69%) subjects), more convenient (26 (100%) subjects) and less
time consuming (25 (96%) subjects). 4 subjects reported side effects with bolus
injection, including self limiting dizziness and sensory disturbance. There was no
evidence of renal impairment. Subjects reported that bolus injection was ‘easier to
use’, ‘more convenient’ and ‘time-saving’.
Conclusion: We suggest that bolus CS via TIVAD should be used more widely,
since it is more convenient than infusion, generally well tolerated and safe. Bolus
is also potentially more cost effective, since less time is required for preparation
and delivery and no need for dilution and ancillaries.
221 Outpatient parenteral antimicrobial therapy (OPAT) in patients
with cystic ﬁbrosis
M.G. Pedersen1, S. Jensen-Fangel1, H. Olesen2, J.E. Petersen1. 1Aarhus University
Hospital, Department of Infectious Diseases, Aarhus N, Denmark; 2Aarhus
University Hospital, Pediatric Department, Aarhus N, Denmark
Objectives: To determine the frequency of complications during outpatient par-
enteral antimicrobial therapy (OPAT) administrated through a peripheral venous
line, PICC line or PORT-A-CATH (PAC).
Methods: Catheter related complications in patients with cystic ﬁbrosis during
OPAT were identiﬁed through a two-year retrospective review of patient ﬁles at
Aarhus University Hospital supplemented by an interview.
Results: Of 167 CF patients about one third underwent OPAT through a peripheral
venous line, PICC-line or PORT-A-CATH. 113 treatment episodes were reviewed,
64 with a peripheral venous line, 23 with PICC line and 26 with PAC. In 64 treat-
ment episodes with the peripheral venous line, 51 (79.7%) used bolus injection and
27 (53.0%) episodes had complications (blockage, dislocation, pain). 13 (20.3%)
treatments by infusion pumps caused no complications. 9/23 (39.1%) treatment
episodes with PICC line had complications (infection, pain, thrombosis) requiring
removal of the PICC line (range 1–201 days). 11/26 (42.3%) treatment episodes
using PAC had complications (infection) requiring the PAC to be removed. The
catheter has been in place from 4–3154 days (some still in place). Allergic reactions
(no anaphylaxis) were experienced in 14/113 (12.4%) of the OPAT treatments and
in 2/113 (1.8%) at initiation of the treatment.
Conclusion: Our data indicate that using an infusion pump to administer the
antibiotic treatment minimized peripheral venous line complications. Percentage
complications leading to removal of the catheter is about the same for PICC-lines
and PACs but the average life-time of the latter is much longer. Allergic reactions
are not a major problem.
222 Successful administration of continuous intravenous b-lactam
therapy for allergic CF patients failing standard antibiotic
desensitization
O. Breuer1, M. Cohen-Cymberknoh1, S. Armoni1, E. Kerem1, D. Shoseyov1.
1Hadassah Hebrew University Medical Center, Pediatrics, Pediatric Pulmonology
and Cystic Fibrosis Center, Jerusalem, Israel
Objectives: To review a new approach of treatment with continuous IV b lactam
antibiotic following a desensitization protocol in allergic CF patients who previously
failed a regular desensitization procedure and treatment course due to severe allergic
reactions.
Methods: A retrospective observational study of all CF patients who underwent
antibiotic desensitization procedures at our CF Center between 2005 and 2013.
Results: 33 desensitization procedures were performed in 9 CF patients involving 6
different antibiotics with 15 different patient/drug combinations. 17 desensitizations
were standard procedures followed by a regular treatment course. 5 of these 17
procedures failed, 3 due to severe allergic reactions occurring during the full treat-
ment course after successfully completing the desensitization. 16 desensitization
procedures, performed in patients who previously failed the standard procedure
or patients at high risk for a life threatening allergic reaction, were followed by
a continuous IV infusion of a beta lactam antibiotic. All 16 procedures were
completed successfully. One adverse event, acute urticaria during the last step of
the desensitization procedure, was reported, no adverse events were reported during
the continuous IV treatment course.
Conclusion: Desensitization followed by continuous IV beta lactam infusion allows
lower dosage, slower dose administration rate and maintenance of low serum drug
levels. This approach appears to be safer than a desensitization followed by a regular
dose treatment course. We recommend utilizing this approach in all patients at high
risk to develop a severe allergic reaction from a b lactam antibiotic.
